Forge Bio licenses optimised enzyme variants from Monash University's Department of Biochemistry to produce complex biologics without living cells, reducing manufacturing timelines by 60%. The approach enables smaller teams to develop cGMP batches for clinical trials. Currently in pre-clinical studies for two rare genetic disorders.